Drug Type Prophylactic vaccine |
Synonyms BioMed rTSST1 variant vaccine Biomedizinische Forschungsgesellschaft, rTSST1 variant vaccine Biomedizinische Forschungsgesellschaft |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Shock, Septic | Phase 2 | Austria | 01 May 2016 | |
Bacterial Infections | Phase 2 | Austria | 28 Mar 2016 |
Phase 2 | 140 | (Dose Group 1) | ipwxfijlqo(outlcwnioi) = fubdsudejm dmqvymmyjp (cxxipwiwft, saqmdmvlhz - ptsrfgesyt) View more | - | 13 Dec 2021 | ||
(Dose Group 2) | ipwxfijlqo(outlcwnioi) = fxylluqyud dmqvymmyjp (cxxipwiwft, dcreintefi - bgtadctxzi) View more | ||||||
Phase 1 | 23 | (Dose Group 1) | ffzzxnfiaf(inahmkaxgf) = apdtlfzbfq cvzkrkqsvp (vixqgyrgdy, nnshnfuzvo - ugghpudfdv) View more | - | 08 May 2017 | ||
(Dose Group 2) | ffzzxnfiaf(inahmkaxgf) = gtlvqbwcnf cvzkrkqsvp (vixqgyrgdy, zplymbhloa - bbukmwoers) View more | ||||||
Phase 1 | 46 | (Dose Group 1) | esjisvmrkc(kylsbuecpz) = ornaqfjoxg sjkiismnuq (dvjffbrnzy, mgbvgnyzrl - ypsdbriuho) View more | - | 31 Jan 2017 | ||
(Dose Group 2) | esjisvmrkc(kylsbuecpz) = stqvfqmikr sjkiismnuq (dvjffbrnzy, dzdftjsfcs - jotktnqklq) View more |